Celularity begins trial of COVID-19 cell therapy

By The Science Advisory Board staff writers

August 5, 2020 -- Celularity has received funding to support a phase I/II clinical trial of human placental hematopoietic stem cell-derived natural killer cells (CYNK-001) for the treatment of COVID-19.

The company was awarded $750,000 by the California Institute for Regenerative Medicine. The funds will be used to evaluate antiviral activities of the cryopreserved product in underserved and disproportionately affected populations with COVID-19.

During the phase I portion, CYNK-001 will be administered intravenously in up to 14 patients in three doses over the course of seven days. Clearance of SARS-CoV-2 and clinical improvement will be evaluated with chest x-ray during the study. The phase II portion will be a randomized, multisite study that will measure multiple doses to determine efficacy and symptom progression.

Celularity received clearance from the U.S. Food and Drug Administration in April to move forward with the study. The University of California, Irvine is the first site to open for patient enrollment.

FDA researchers describe lessons learned from COVID-19 immunology
Key immunological factors underlying the clinical stages of COVID-19 that could be targeted by therapeutic drugs were outlined in a review by U.S. Food...
Kleo, Green Cross collaborate on COVID-19 NK combination therapy
Kleo Pharmaceuticals is joining forces with Green Cross LabCell of South Korea to advance testing of natural killer (NK) cell therapies as a potential...

Copyright © 2020 scienceboard.net

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter